Contraindications to Sodium Valproate in Females of Reproductive Age

Primary Contraindication

Sodium valproate is absolutely contraindicated in women of childbearing potential due to its significant teratogenic effects and risk of developmental disorders in exposed children, and must not be used unless there is no suitable alternative and a pregnancy prevention program is implemented, as recommended by the American Academy of Neurology 1, 2
It is classified as having an absolute contraindication for women who are or may become pregnant, according to the American College of Obstetricians and Gynecologists 1, 3

Valproate use in women is associated with menstrual irregularities, such as amenorrhea, oligomenorrhea, and prolonged cycles, affecting approximately 45% of women on valproate monotherapy, as reported by the European Journal of Neurology 4
Valproate use is also associated with an increased incidence of polycystic ovaries and elevated serum testosterone levels in 30% of women taking valproate, according to the Endocrine Society 4

For migraine prevention, beta-blockers, such as propranolol and metoprolol, candesartan, or topiramate are preferred first-line options, as recommended by the American Headache Society 1
For epilepsy, alternative anticonvulsants should be considered based on seizure type and individual factors, according to the American Academy of Neurology 3

Comprehensive preconception counseling is essential for all women with epilepsy or other conditions typically treated with valproate, as recommended by the Centers for Disease Control and Prevention 5
If a woman is already taking valproate and planning pregnancy, medication should be switched to a safer alternative before conception, according to the American College of Obstetricians and Gynecologists 3, 5

The American College of Cardiology recommends that women taking valproate use progestin-only IUDs (levonorgestrel) or copper IUDs as first-line contraceptive options due to their high effectiveness (>99%) and no drug interactions 6
The American Heart Association suggests that progestin subdermal implants (etonogestrel) are also highly effective (>99%) and can be used as a first-line option for women taking valproate 7

Progestin-only pills are effective (90%) but require perfect adherence, making them a second-line option for women taking valproate 7, 6
Estrogen-containing contraceptives have insufficient efficacy (93-97% with typical use) and are associated with a 3-8% failure rate, which is unacceptable for women taking valproate due to the high risk of major malformations 7
The American College of Cardiology states that estrogen-containing contraceptives should be avoided in women taking valproate due to the high risk of stroke and major malformations 7

For women with specific risk factors such as age >35 years, tobacco use, hypertension, or migraine with aura, progestin-only or non-hormonal methods are recommended due to the increased risk of stroke 7
The American College of Cardiology recommends that women with congenital heart disease at high thrombotic risk avoid estrogen-containing contraceptives due to the potential harm 8, 9

Women planning pregnancy should achieve optimal seizure control on the safest possible antiepileptic drug regimen before conception, as recommended by the American Family Physician (2013) 10